HealthStream (NASDAQ: HSTM) and Cancer Genetics (NASDAQ:CGIX) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitabiliy, analyst recommendations, dividends, risk, valuation and institutional ownership.
This is a breakdown of recent recommendations for HealthStream and Cancer Genetics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
HealthStream presently has a consensus price target of $26.00, suggesting a potential upside of 15.10%. Cancer Genetics has a consensus price target of $6.00, suggesting a potential upside of 66.67%. Given Cancer Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Cancer Genetics is more favorable than HealthStream.
Risk and Volatility
HealthStream has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Cancer Genetics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
This table compares HealthStream and Cancer Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
76.8% of HealthStream shares are held by institutional investors. Comparatively, 12.9% of Cancer Genetics shares are held by institutional investors. 21.1% of HealthStream shares are held by insiders. Comparatively, 21.3% of Cancer Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares HealthStream and Cancer Genetics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|HealthStream||$238.45 million||3.02||$23.61 million||$0.14||161.36|
|Cancer Genetics||$27.95 million||2.55||-$11.95 million||($1.17)||-3.08|
HealthStream has higher revenue and earnings than Cancer Genetics. Cancer Genetics is trading at a lower price-to-earnings ratio than HealthStream, indicating that it is currently the more affordable of the two stocks.
HealthStream beats Cancer Genetics on 8 of the 12 factors compared between the two stocks.
HealthStream, Inc. (HealthStream) provides workforce, patient experience and provider solutions for healthcare organizations. The Company operates in three segments: HealthStream Workforce Solutions, HealthStream Patient Experience Solutions and HealthStream Provider Solutions. HealthStream’s products and services are organized into three segments: Workforce Solutions, Patient Experience Solutions, and Provider Solutions. HealthStream’s solutions are provided to a range of customers within the healthcare industry across the continuum of care. Delivered primarily as Software-as-a-Service (SaaS), the Company’s solutions focus on challenges facing the healthcare workforce and healthcare organizations, including the need to manage, retain, engage and develop healthcare workforce talent; meet compliance requirements; manage ongoing medical staff credentialing and privileging processes, and deliver patient experiences of care in healthcare organizations.
About Cancer Genetics
Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.
What are top analysts saying about HealthStream Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for HealthStream Inc. and related companies.